Literature DB >> 34358538

Therapeutic and delivery strategies of phytoconstituents for renal fibrosis.

Huan Xu1, Tianyi Wu2, Leaf Huang3.   

Abstract

Chronic kidney disease (CKD) is one of the most common diseases endangering human health and life. By 2030, 14 per 100,000 people may die from CKD. Renal fibrosis (RF) is an important intermediate link and the final pathological change during CKD progression to the terminal stage. Therefore, identifying safe and effective treatment methods for RF has become an important goal. In 2018, the World Health Organization introduced traditional Chinese medicine into its effective global medical program. Various phytoconstituents that affect the RF process have been extracted from different plants. Here, we review the potential therapeutic capabilities of active phytoconstituents in RF treatment and discuss how phytoconstituents can be structurally modified or combined with other ingredients to enhance efficiency and reduce toxicity. We also summarize phytoconstituent delivery strategies to overcome renal barriers and improve bioavailability and targeting.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Combined administration; Delivery strategies; Phytoconstituents; Renal fibrosis; Structural modification

Mesh:

Substances:

Year:  2021        PMID: 34358538     DOI: 10.1016/j.addr.2021.113911

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  7 in total

Review 1.  Traditional Chinese medicine promotes bone regeneration in bone tissue engineering.

Authors:  Zheng-Rong Gao; Yun-Zhi Feng; Ya-Qiong Zhao; Jie Zhao; Ying-Hui Zhou; Qin Ye; Yun Chen; Li Tan; Shao-Hui Zhang; Yao Feng; Jing Hu; Ze-Yue Ou-Yang; Marie Aimee Dusenge; Yue Guo
Journal:  Chin Med       Date:  2022-07-20       Impact factor: 4.546

2.  Network Pharmacology and Experimental Verification Strategies to Illustrate the Mechanism of Jian-Pi-Yi-Shen Formula in Suppressing Epithelial-Mesenchymal Transition.

Authors:  Yuan Zhao; Xiangbin Li; Fochang Wang; Shiying Huang; Hanqian Du; Shunmin Li; Jianping Chen
Journal:  Front Pharmacol       Date:  2022-05-17       Impact factor: 5.988

Review 3.  Potential Therapeutic Effect and Mechanisms of Mesenchymal Stem Cells-Extracellular Vesicles in Renal Fibrosis.

Authors:  Chunling Liao; Guangyong Chen; Qian Yang; Yiping Liu; Tianbiao Zhou
Journal:  Front Cell Dev Biol       Date:  2022-03-11

4.  Estradiol Ameliorates Acute Kidney Ischemia-Reperfusion Injury by Inhibiting the TGF-βRI-SMAD Pathway.

Authors:  Lian Ren; Fang Li; Ziyang Di; Yan Xiong; Shichen Zhang; Qing Ma; Xiaoen Bian; Zhiquan Lang; Qifa Ye; Yanfeng Wang
Journal:  Front Immunol       Date:  2022-02-24       Impact factor: 7.561

5.  Bioinformatics analysis of the potential regulatory mechanisms of renal fibrosis and the screening and identification of factors related to human renal fibrosis.

Authors:  Cixiao Wang; Shaobo Wu; Jiang Li; Yuexian Ma; Youqun Huang; Na Fang
Journal:  Transl Androl Urol       Date:  2022-06

6.  Human umbilical cord mesenchymal stem cell-derived exosomal miR-335-5p attenuates the inflammation and tubular epithelial-myofibroblast transdifferentiation of renal tubular epithelial cells by reducing ADAM19 protein levels.

Authors:  Zhenhua Qiu; Zhihui Zhong; Yuehan Zhang; Haoling Tan; Bo Deng; Guohuang Meng
Journal:  Stem Cell Res Ther       Date:  2022-07-28       Impact factor: 8.079

7.  Heidihuangwan alleviates renal fibrosis in rats with 5/6 nephrectomy by inhibiting autophagy.

Authors:  Ying-Ying Li; Zeng-Hui Tian; Guang-Hui Pan; Ping Zhao; De-Jun Pan; Jun-Qing Zhang; Li-Ying Ye; Fa-Rong Zhang; Xiang-Dong Xu
Journal:  Front Pharmacol       Date:  2022-09-09       Impact factor: 5.988

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.